Sinovac Biotech’s (SVA) “Buy” Rating Reiterated at HC Wainwright

Posted by James Quigley on Sep 11th, 2026

HC Wainwright reissued their buy rating on shares of Sinovac Biotech (NASDAQ:SVA – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $1.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $6.00.

Sinovac Biotech Stock Performance

Sinovac Biotech stock opened at $6.47 on Tuesday. The business’s 50-day simple moving average is $6.47 and its 200 day simple moving average is $6.47. The company has a current ratio of 6.07, a quick ratio of 5.97 and a debt-to-equity ratio of 0.04. Sinovac Biotech has a 12-month low of $5.73 and a 12-month high of $8.75.

Institutional Investors Weigh In On Sinovac Biotech

Institutional investors have recently modified their holdings of the business. California Public Employees Retirement System bought a new stake in shares of Sinovac Biotech during the second quarter worth approximately $445,000. Geode Capital Management LLC bought a new position in Sinovac Biotech in the second quarter valued at approximately $179,000. Finally, Bank of America Corp DE acquired a new stake in Sinovac Biotech during the 2nd quarter worth $38,000.

About Sinovac Biotech

(Get Free Report)

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine.